Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $16.00 | Buy | B. Riley Securities |
| 3/13/2025 | Buy → Hold | Needham | |
| 5/16/2024 | $20.00 | Hold → Buy | Needham |
| 11/16/2023 | Hold | Needham | |
| 12/21/2022 | $9.00 | Underweight | Barclays |
| 6/17/2022 | $20.00 | Neutral | JP Morgan |
| 3/18/2022 | Neutral | Guggenheim |
B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00
Needham downgraded ZimVie from Buy to Hold
Needham upgraded ZimVie from Hold to Buy and set a new price target of $20.00
PALM BEACH GARDENS, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced the launch of its RealGUIDE® Software Suite and Implant Concierge® service in Japan. The launch of RealGUIDE and Implant Concierge in Japan expands dentists' access to a unique digital dental implant ecosystem—from implant planning to placement—with vertically integrated, end-to-end solutions. The dental implant market opportunity in Japan is significant, and Japan is ZimVie's largest market in the APAC region. "We are proud to offer an innovative digital dentistry solution tailored to the needs of the Japanese market," said Tai
PALM BEACH GARDENS, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today announced management will participate in the upcoming Stifel 2025 Jaws & Paws Conference. Management will be presenting on Wednesday, May 28, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time. A live webcast of the event, as well as an archived recording will be available on ZimVie's investor website at investor.zimvie.com. About ZimVieZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and res
Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025